Pediatrics | Physician's Weekly


FDA Extends Exenatide Indication to Treat Kids with T2D

GLP-1 receptor agonist OK’d for ages 10-17 years The FDA approved an expanded indication for extended-release exenatide (Bydureon and Bydureon BCise) to improve glycemic control in pediatric patients ages 10-17 years with...

Why Is Flu Vax Uptake So Dismal for Hospitalized Kids?

Gap between vaccines ordered and shots given remains after use of clinical decision support tool Is vaccinating hospitalized children against influenza a common practice prior to discharge? It would seem to be a no...